Abstract
Since its identification as a coreceptor for viral entry into CD4 + cells, CCR5 has represented a possible therapeutic target in the battle against HIV-1. In the current article, the physiological function of CCR5, its use by HIV-1 to enter target cells, and its role in immune activation and susceptibility to disease are summarized. Genetic mutations of the CCR5 gene, both naturally occurring and therapeutically induced, are outlined along with the potential therapeutic application of CCR5 blockade. The clinical trial of the CCR5 antagonist maraviroc, currently being undertaken by the present authors' research group, is also reviewed.
| Original language | English |
|---|---|
| Pages (from-to) | 1-10 |
| Number of pages | 10 |
| Journal | Journal of Viral Entry |
| Volume | 4 |
| Issue number | 1 |
| Publication status | Published - 2010 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Nature and function of CCR5 in immune activation, HIV-1 entry, and targeted therapeutics'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver